MET and cancer: Especially for MET fusions in cancers, as shown in Fig. 1C, although it was rare among all types of cancers, NSCLC patients had a significantly higher incidence of MET fusions as well as the types of MET fusions, which are considered putative driver mutations (Fig. 1D).